FindTrial
Sign In

Immune checkpoint inhibitors for ocular melanoma

Immune checkpoint inhibitors for ocular melanoma - Immune checkpoint inhibitors for ocular melanoma

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000047431
Enrollment
Unknown
Registered
2022-04-07
Start date
2022-04-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular melanoma

Interventions

None listed

Sponsors

Yokohama City University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with ocular melanoma who were treated with ICI

Exclusion criteria

Exclusion criteria: Patients with ocular melanoma who were treated with ICI as adjuvant/neoadjuvant therapy

Design outcomes

Primary

MeasureTime frame
ORR, DCR, PFS, and OS among patients with ocular melanoma who were treated with ICI.—

Countries

Japan

Contacts

Public ContactNobuyuki Horita

Yokohama City University Hospital Chemotherapy Center

horitano@yokohama-cu.ac.jp045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026